# AB-1015

Source: https://onco.cc/drugs/ab-1015/  
OnCo record `ab-1015` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AB-1015 is an experimental autologous Integrated Circuit T cell therapy from Arsenal Biosciences, in phase 1 trials for platinum-resistant high-grade serous ovarian, fallopian tube and primary peritoneal cancer; its current status is not stated.

## Summary

AB-1015 is an autologous Integrated Circuit T (ICT) cell therapy from Arsenal Biosciences. An autologous Integrated Circuit T cell therapy tested in platinum-resistant ovarian cancer; the sources reached do not name its targets. Its furthest stage is phase 1, for platinum-resistant high-grade serous ovarian, fallopian tube and primary peritoneal cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT05617755 terminated; registry reason: 'Active patients have been rolled over to a separate LTFU study.' Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: AB-1015
- Modality: Autologous Integrated Circuit T (ICT) cell therapy
- Mechanism: An autologous Integrated Circuit T cell therapy tested in platinum-resistant ovarian cancer; the sources reached do not name its targets.

## Sources

- Arsenal Biosciences: arsenalbio.com: https://arsenalbio.com/2024/04/30/arsenal-biosciences-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-ab-2100-in-development-as-a-treatment-for-clear-cell-renal-cell-carcinoma/
- Arsenal Biosciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05617755
- ClinicalTrials.gov: trials of AB-1015: https://clinicaltrials.gov/search?intr=AB-1015

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Arsenal Biosciences](https://onco.cc/companies/arsenal-bio/)
- trials: [AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer](https://onco.cc/trials/nct05617755/)

---
JSON: https://onco.cc/api/v1/entities/ab-1015.json